Axsome Therapeutics, Inc.

Axovant Therapeutics Misses on Revenue, Stock Up 7.86%

Axovant Therapeutics reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, with shares rising by 7.86%. The company did not disclose revenue figures or provide guidance, leaving investors to focus on the progress of its clinical programs. The stock's increase suggests that investors are optimistic about the company's future potential despite the lack of detailed financial metrics.